Association of checkpoint inhibitor–induced toxic effects with shared cancer and tissue antigens in non–small cell lung cancer
Importance Immunotherapy with checkpoint inhibitors targeting the PD-1 (programmed cell
death 1) axis has brought notable progress in patients with non–small cell lung cancer
(NSCLC) and other cancers. However, autoimmune toxic effects are frequent and poorly
understood, making it important to understand the pathophysiologic processes of
autoimmune adverse effects induced by checkpoint inhibitor therapy. Objective To gain
mechanistic insight into autoimmune skin toxic effects induced by anti–PD-1 treatment in …
death 1) axis has brought notable progress in patients with non–small cell lung cancer
(NSCLC) and other cancers. However, autoimmune toxic effects are frequent and poorly
understood, making it important to understand the pathophysiologic processes of
autoimmune adverse effects induced by checkpoint inhibitor therapy. Objective To gain
mechanistic insight into autoimmune skin toxic effects induced by anti–PD-1 treatment in …